RLMD Jan 2025 55.000 call
| Previous Close | 0.2000 |
| Open | 0.2000 |
| Bid | 0.0000 |
| Ask | 0.6500 |
| Strike | 55.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.2000 - 0.2000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 22 |
PR NewswireRelmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, will participate in a fireside chat at the 2024 Goldman Sachs Global Healthcare Conference in Miami, Florida on Wednesday, June 12, 2024, at 11:20am ET. Management will also host one-on-one investor meetings. Please find additional details about the event below.
- PR Newswire
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in a fireside chat on Thursday, June 6, 2024, at 7:30am ET at the 2024 Jefferies Global Healthcare Conference in New York, NY. Management will also host one-on-one investor meetings. Please find additional details about the event below.
Insider MonkeyRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript May 10, 2024 Relmada Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). LifeSci Advisors: Sergio Traversa – Chief Executive Officer Maged Shenouda – Chief Financial Officer Andrew Cutler – Senior […]
